Ser172
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser172  -  AMPKA1 (human)

Site Information
KIADFGLsNMMsDGE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15407586

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 4 , 5 , 6 , 7 , 8 ) , phospho-antibody ( 1 , 3 ) , western blotting ( 1 , 2 , 3 )
Disease tissue studied:
bone cancer ( 2 ) , glioblastoma multiforme ( 3 ) , glioma ( 3 ) , breast cancer ( 2 ) , hypopharyngeal cancer ( 1 ) , lung cancer ( 7 , 8 ) , non-small cell lung cancer ( 7 , 8 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
DNAPK (human) ( 2 )
Treatments:
A-769662 ( 2 ) , cisplatin ( 1 ) , compound_C ( 2 ) , glucose_starvation ( 2 , 3 ) , metformin ( 1 ) , NU7026 ( 3 ) , NU7441 ( 2 )

Downstream Regulation
Effects of modification on AMPKA1:
activity, induced ( 3 )
Effects of modification on biological processes:
signaling pathway regulation ( 3 )

References 

1

Xie L, et al. (2020) Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. Signal Transduct Target Ther 5, 56
32433544   Curated Info

2

Puustinen P, et al. (2020) DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy. Autophagy, 1-18
31983282   Curated Info

3

Shiga S, et al. (2019) DNA-PKcs is activated under nutrient starvation and activates Akt, MST1, FoxO3a, and NDR1. Biochem Biophys Res Commun
31679687   Curated Info

4

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

5

Mulhern D (2012) CST Curation Set: 13830; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

6

Mulhern D (2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

7

Rikova K (2010) CST Curation Set: 9456; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

8

Rikova K (2010) CST Curation Set: 9471; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info